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Abstract
In silico prediction of drug-target interactions from heterogeneous biological data can advance our system-level search for
drug molecules and therapeutic targets, which efforts have not yet reached full fruition. In this work, we report a systematic
approach that efficiently integrates the chemical, genomic, and pharmacological information for drug targeting and
discovery on a large scale, based on two powerful methods of Random Forest (RF) and Support Vector Machine (SVM). The
performance of the derived models was evaluated and verified with internally five-fold cross-validation and four external
independent validations. The optimal models show impressive performance of prediction for drug-target interactions, with
a concordance of 82.83%, a sensitivity of 81.33%, and a specificity of 93.62%, respectively. The consistence of the
performances of the RF and SVM models demonstrates the reliability and robustness of the obtained models. In addition,
the validated models were employed to systematically predict known/unknown drugs and targets involving the enzymes,
ion channels, GPCRs, and nuclear receptors, which can be further mapped to functional ontologies such as target-disease
associations and target-target interaction networks. This approach is expected to help fill the existing gap between
chemical genomics and network pharmacology and thus accelerate the drug discovery processes.
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Introduction
As is well known, the identification of novel promising drugs
and targets, as a time-consuming and efforts-costing process, is
quite a hard goal to achieve. For instance, in 2006 only 22 new
molecular entities were approved by the Food and Drug
Administration (FDA) despite the astronomical research and
development expenditures as high as up to $93 billion USD [1].
One crucial cause for this situation may be the existence of
abundant potential drug-target interactions which have not been
discovered so far. Although various biological assays are becoming
available, experimental qualification of drug-target interactions
remains challenging and expensive even nowadays [2,3]. Actually,
it is estimated that the set of all possible small molecules has
already consisted of more than 10
60 compounds [4], which creates
incredibly great difficulties in comprehensive understanding of the
interface between chemical space and biological systems [5].
Furthermore, plentiful evidences have exhibited that the patterns
of drug-target interactions are too various to be understood as
simple one-to-one events [6,7], due to the reasons of (1)
structurally different drugs might express similar activities and
bind to the same proteins, and (2) one drug might exert impacts on
multiple targets. Hence, there is a strong incentive to develop
appropriate theoretical computational tools which are capable of
detecting the complex drug-target interactions.
Currently, the most widely used methods are the ligand-based
virtual screening (LBVS), structured-based virtual screening
(SBVS) and the text mining-based approach. Theoretically, LBVS
compares candidate ligands with the known drugs of a target
protein to find new compounds using statistical tools [8,9].
However, the performance of LBVS is often poor when the
number of known active molecules for a target of interest is too
small. Moreover, this method generally has difficulty in identifying
drugs with novel structural scaffolds that differ from the reference
molecules. Different from LBVS, SBVS is constrained by the
available crystallographic structure of target, thus hindering the
prescreening process by in silico tools. And this problem is
particularly serious for those membrane proteins, like the GPCRs
(G-protein coupled receptors) whose 3D structure information is
still unavailable up to date [10]. The above two methods are
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molecule-target associations, while the text mining-based ap-
proach is a way to gather information previously existing in the
literature that would probably have been missed. Additionally, it
also suffers from an inability to detect new biological findings, and
their efficiency is generally hampered by the redundancy of the
compound and gene names in literature [11]. Therefore, the
genome-wide application of LBVS, SBVS and texting mining-
based methods still has many limitations.
An effective means that might overcome these problems is not
to considerate each drug or target independently from other drugs
or targets, but to take the standpoint of chemical genomics [12]
which could open up new opportunities to identify new drug leads
or therapeutic targets instead. Chemical genomics aims at
exploiting the whole chemical space, which corresponds to not
only the space of the small molecules but also of those proteins
(drug targets) interacting with the molecules [13]. Recently, several
chemical genomics approaches, including the ligand-based, target-
based or target-ligand methods have been developed to predict the
interactions between compounds and proteins [14–20]. The
ligand-based method that integrated the protein targets was
designed at the level of families or subfamilies which is appropriate
for some specific protein families such as GPCRs [14,15]. Based
on the ligand binding site similarity, Frimurer et al developed a
target-based approach which clustered the receptors and pooled
together the known ligands for each cluster to infer shared ligands
[16]. Different from these two approaches, the target-ligand
approach combines the ligand chemical space, target space and
the currently known drug-target networks information to construct
a complex forecast system, with purpose to predict ligands or
targets for a given target or ligand without prior attempting to
define a special set of similar receptors or ligands. For instance, the
amino acid sequences, 2-dimensional chemical structures and
mass-spectrometry data have been collected together to build a
statistical method for predicting compound-protein interactions
based on 519 approved drugs and their 291 associated targets [17].
Similarly, the chemical functional groups and biological features
have also been adopted to establish the classification models for
predicting the drug-target interaction network [18]. Interestingly,
without the negative samples, the semi- supervised machine
learning algorithm NetLapRLS has been developed based on
heterogeneous biological data, which could effectively predict the
interaction of each chemical-protein pair [19]. Furthermore, based
on DrugBank database, the sets of chemical substructures and
protein domains have also been collected and effectively analyzed
using Sparse Canonical Correspondence Analysis (SCCA) and
Support Vector Machine (SVM) methods to identify molecular
recognition rules between drugs and targets [20]. However, all
these aforementioned methods might suffer from the small
receptor space which only focused on certain protein families or
the limited chemical space only covered by the FDA approved
drugs.
To predict the drug-target interactions, we have designed a set
of in silico tools by incorporating the chemical, genomic and
pharmacological information into an integrated framework using
the largest available dataset of DrugBank database. The predic-
tions are based on extraction of conserved patterns from
subdivided interaction vectors involving both proteins and their
corresponding ligands (protein and ligand encoding vectors). A
notable advantage of these tools is that it allows us to take proteins
of different families into accounts thanks to the choice of protein
encoding by the structural and physicochemical properties derived
from their primary sequences. The powerful ensemble-based
method, i.e., Random Forest (RF), was adopted to construct the
models, which is more robust against the overfitting problem and
performs more efficiently for large-scale data sets when compared
with some traditional statistical methods such as Linear Discrim-
inant Analysis (LDA), the Partial Least Square (PLS) and Aritificial
Neural Network (ANN) [21]. The performance of the RF
algorithm was compared with that of the SVM method to validate
the reliability of the obtained models. The validated models were
further employed to systematically predict the known/unknown
drugs or targets involving the enzymes, ion channels, GPCRs and
nuclear receptors, etc. Particularly, we successfully identify
unrelated target proteins of chemical compounds using RF
method, and meanwhile, effectively distinguish the novel scaffold
hopping ligands of the receptors, which will significantly facilitate
the drug-target discovery.
Materials and Methods
Benchmark Dataset
Dataset for drugs and targets with known pharmacological
interactions were extracted from DrugBank database (http://
drugbank.ca/, accessed on June 1st 2011), which so far contains
6707 drug entries including 1436 FDA-approved small molecule
drugs, 134 FDA-approved biotech (protein/peptide) drugs, 83
nutraceuticals and 5086 experimental drugs. Additionally, 4228
non-redundant protein (i.e. drug target/enzyme/transporter/
carrier) sequences are also potentially linked to these entries. To
confirm the quality of this data set, we have carefully compared
this database with other databases such as STITCH, SuperTarget
and KEGG database, as well as the literature [22,23]. In the
process of building dataset, some drugs and targets (such as nitric
oxide and ribosomal protein Thx) were omitted since their
chemical descriptors cannot be calculated (details are provided in
Supporting Information S1). As a result, a dataset including 6511
drugs and 3987 targets was applied in this work as the benchmark
dataset (detailed information of these drugs and targets was given
in Supporting Information S2 and S3).
Chemical and Protein Descriptors Calculation
Chemical descriptors were calculated using DRAGON pro-
gram (http://www. talete.mi.it/index.htm), which was designed to
execute the computation of 20 molecular descriptors categories
including 1664 descriptors such as constitutional descriptors,
topological descriptors, 2D autocorrelations, topological charge
indices, eigenvalue-based indices and molecular properties et al.
(details are referred to DRAGON manual). In this work, the
charge descriptors and some other descriptors such as IC2, TIC2,
SIC2 and CIC2 were discarded as these descriptors cannot be
calculated for all drugs (Supporting Information S4). Additionally,
in this work, some constant descriptors and near constant
descriptors were also removed. And finally, 1080 descriptors were
used for subsequent analysis. The protein sequence descriptors
were calculated using PROFEAT WEBSEVER (http://jing.cz3.
nus.edu.sg/cgi-bin /prof/prof.cgi), involving descriptors like
Moran autocorrelation, Dipeptide composition and so on [24].
In order to handle varying sequence length and to extract protein
features to the largest extent, each protein was represented by a set
of structural and physicochemical descriptors derived from their
primary sequences including Amino acid composition descriptors;
Dipeptide composition descriptors; Autocorrelation descriptors;
Composition, Transition, Distribution descriptors; Quasi-se-
quence-order descriptors; Amphiphilic pseudo-amino acid com-
position descriptors and Total amino acid properties descriptors,
which can transform the changeable length of protein sequence to
a standard feature vector of 1080 dimensions. The detailed
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Information S5.
Construction of Training and Test Sets
In order to obtain the experimental dataset, we have
constructed a set of numerical vectors for the drug-target pairs
(both for positive and negative samples) by concatenating chemical
descriptors and protein descriptors. The positive samples were
constructed by the known interaction relationships that obtained
from DrugBank database. As the information about negative
samples was unavailable, a production procedure for negative
samples was designed as follows: (I) re-coupled all drugs and
targets in the benchmark dataset into pairs, (II) removed those
drug-protein pairs existed in the positive samples, and keep the
remaining pairs which represent the non-interaction space, (III)
randomly picked the negative pairs from the non-interaction space
until they reached the same number as the positive pairs. As a
result, 13597 positive samples and 13597 negative samples were
produced as the experimental dataset. Based on this experimental
dataset, we have developed four models according to different
external validations, i.e., Model I for ‘‘general’’ prediction, Model
II for ‘‘new-drug vs known-target’’ prediction, Model III for ‘‘new-
target vs known-drug’’ prediction and Model IV for ‘‘new-drug vs
new-target’’ prediction. Here, the ‘‘general’’ means the Model I is
an universal model, which can be applied for all possible
predictions. And the drugs and targets in the training set are
called known drugs and known targets, whereas those not included
are termed as new drugs and new targets.
In detail, the procedures for producing training and test sets of
the four models were performed as follows: For the Model I, the
training and test sets were generated by randomly splitting the
experimental dataset. For the other three models, the processes of
creating the training and test sets involved two steps. Firstly, the
experimental dataset was randomly split into two parts: an initial
training set and an initial test set. Then, the training and test sets of
Model II were obtained by moving the samples including the
known drugs/new targets from the initial test set to the initial
training set. The training and test sets of Model III were derived
by shifting the samples that contain the new drugs/known targets
from the initial test set to initial training set. And the training and
test sets of Model IV were produced by deleting the samples
including the known drugs/known targets from the initial test set.
Finally, we got the training sets I, II, III, and IV of positive
samples 10877, 11148, 11237, 6933 and negative samples 10878,
10593, 10605, 9402, respectively. The test sets I, II, III, and IV
contained positive samples 2720, 2449, 2360, 446 and negative
samples 2719, 3004, 2992, 596, respectively. In this study, all
experimental data were separately pre-scaled to the range from
21 to 1. The information of experimental dataset was provided in
Supporting Information S6.
Random Forest
Recently, attention has been concentrated on using ‘‘ensemble
learning’’ method to generate classifiers [25–28]. As a relatively
new ensemble tool, Random Forest algorithm is firstly proposed
by Leo Breiman and Adele Cutler [21] which has four
predominant advantages in dealing with pattern recognition
problem, i.e., 1) it runs efficiently on high dimensional multiclass
datasets, 2) it does not overfit when the number of features exceeds
the number of samples, 3) it is robust against noise compared to
the boosting method, 4) it adopts the Bagging (bootstrap
aggregating) method which can maintain the strength of the trees
while reducing their correlation and improve the prediction
accuracy.
In addition, RF can be developed as a classifier that consists of
many decision trees and outputs the class that is the mode of the
classes output by individual trees. Let the number of training cases
be N, and the number of variables in the classifier be M, the
process of the RF classifier is as follows: (I) The variable mtry which
determines the decision at a node of the tree is defined to be less
than M. (II) Draw n bootstrap samples B1,B2,   ,Bn fg from the
original training set. (III) Set up an unpruned tree
Tp(p~1,2,   n) with each training set Bp. At each node of the
tree, randomly choose mtry variables on which to make the
decision at that node. And then calculate the best splits based on
these mtry variables. (IV) Predict the class of input samples by the
majority votes of the N trees.
Two tuning parameters, i.e., the number of trees and mtry, are
important in establishing the RF models. Usually, 500 trees are
sufficient to generate a model for most cases [21]. mtry is the
number of descriptors randomly sampled as candidates for
splitting at each node during the tree induction, ranging from 1
to the total number of the variables (p). Empirically, the default
value of mtry (
ﬃﬃﬃ
p
p
for classification) was assigned to building
models, since the performance of RF seems to change very little
over a wide range of values except the extreme 1 and p [21,25–
28]. Normally, the performance of a pattern recognition model
might be severely affected if those irrelevant descriptors are not
removed prior to the model training. However, it has been shown
that the feature selection is not quite necessary in building the RF
models [25–28], as the Out-Of-Bag (OOB) error is used to get the
estimates of feature importance. In this work, the Random Forest
soft package, which was developed by Leo Breiman et al., was used
to build the RF prediction models (available at http://www.stat.
berkeley.edu/users/breiman/).
Support Vector Machine
SVM represents a class of statistical learning algorithms that
have been widely used in bioinformatics and chemometrics due to
its remarkable generalization performance in managing linearly
non-separable problems [29–31]. Since its theory had been
thoroughly described in the literature [32], only a brief description
of the method is given here. Given n samples, each of which has an
m-dimensional feature vector (xi~(x1
i ,x2
i    xm
i )) and the two
classes (yi[ -1,1 fg ) respectively representing the interaction and
non-interaction, the classifier is produced as follows:
f(x)~sgn(
X p
i~1
aiyik(xi,x)zb0), ð1Þ;
where x is the new object to be classified, p is the number of the
training samples, f(x) is a decision function and k(xi,x) is a kernel
function that shows similarity between two vectors. The param-
eters b0 and ai are obtained by solving a quadratic programming
problem. For linearly separable cases, SVM constructs a maximal
margin hyper-plane to separate the positive samples (interactive
pairs of compound-protein) from the negative ones (non-interac-
tive pairs of compound- protein). A new pair of compound-protein
can be classified as a positive or negative when
sgn(
P p
i~1
aiyixixzb0) is positive or negative, respectively. For not
linearly separable data, SVM maps the input numerical vectors
into a higher dimensional feature space to construct a maximal
margin hyper-plane that separate the positive from the negative
samples by using a kernel function. And the interactions between
the compounds and proteins can be classified as a positive or
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P p
i~1
aiyik(xi,x)zb0) is positive or negative,
respectively. In this study, we have used a portion of the codes
from the LIBSVM suite of programs (http://www.csie.ntu.edu.
tw/,cjlin/libsvm), which employs a modified version of the
sequential minimal optimization (SMO) algorithm [33]. The soft
margin SVM was employed to construct the statistical models.
Generally, four kinds of kernel functions, i.e. linear function,
polynomial function, sigmoid function and radial basis function
(RBF), are available to perform prediction. Empirical studies have
demonstrated that the RBF outperforms the other three kinds of
kernel functions [34]. Hence, this work adopted the RBF to
perform inference process. The regularization parameter C and
the kernel parameter s were selected based on the overall accuracy
of the internal five-fold cross-validation using the grid search
method. The simulation process was developed by using
PYTHON (version 3.2) and GNUPLOT (version 4.4).
Model Validation
In order to fully assess the suitability of these in silico models,
both the internal and external validations methods were employed.
Firstly, all developed models were evaluated by internal five-fold
cross-validation. During this process, the training set was
randomly divided into five subsets of approximately equal size,
where four subsets were selected as the training set to develop a
model and the remaining samples as test set for the model
validation. The process was repeated five times so that every subset
was used as the testing set once. Secondly, we carried out four
external independent validations for all models using different test
sets. Finally, the performance of the RF models was compared
with that of the corresponding models built by SVM method.
Measurement of Prediction Quality
In the case of classification, the assessment of the prediction
quality of statistical models is typically performed on the basis of
several parameters [35]. The sensitivity (SE) of the present models
describes the ratio of correctly predicted interactions to the total
number of the drug-target interactions, whereas the specificity (SP)
refers to the ratio of correctly predicted non-interactions to the
total number of the drug-target non-interactions. The integrated
parameter concordance (the ratio of correctly predicted com-
pound-protein pairs to the total number of tested compound-
protein pairs, CO) gives an overall model performance value.
SE~
TP
TPzFN
, ð2Þ;
SP~
TN
TNzFP
, ð3Þ;
CO~
TPzTN
TPzTNzFPzFN
: ð4Þ;
Here, TP and FP are the quantity of the true and false interactions
between the drugs and targets, respectively, TN and FN are the
quantity of true and false non-interactions between the drugs and
targets, respectively. In addition, the performance was also
evaluated by using a receiver operating curve (ROC), which is
obtained by varying the threshold separating positives from
negatives and plotting the TP rate (sensitivity) versus the FP rate
(1-specificity). The binding score of RF model in this work was
defined as the number of tree vote for 1 (interaction) divided by the
number of tree vote for 21 (non-interaction). For all of these
statistics, a larger number indicates a better performance of the
model. Figure 1 depicts the flowchart of the modeling procedure.
Results
Recently, various in silico methods have been developed to
analyze multiple compound-protein interactions. QSAR (quanti-
tative structure-activity relationship) is the most commonly
adopted. However, QSAR requires the knowledge of sufficient
enough ligands of a given receptor with respect to the complexity
of the ligand/non-ligand separation to produce accurate predic-
tors. If few or no ligands are available for a receptor, molecular
docking is an alternative approach, which in turn requires the 3D
structure of the target. To overcome the shortcomings of these two
approaches, several statistical models have been developed to
predict the interactions, such as the binary classification models
[36,37] and the supervised bipartite graph inference ones [38,39].
Although these methods have effectively accomplished the
potential drug-target interaction prediction, their applicability
domain may still be limited by the small chemical and biological
space.
For the purpose of broadening the scope of application of these
predictors, we developed a set of in silico models based on the large-
scale heterogeneous biological data. Our models concatenate the
chemical structural and physicochemical properties with the
protein structural and physicochemical properties to discriminate
the binding patterns from the non-binding patterns. Generally, it is
difficult to assess the performance of a chemical and protein
feature encoding method in a direct manner. However, if the
encoding are biologically meaningful and enable to capture
relevant information with respect to receptor-ligand recognition,
one would expect that they present good generalization properties.
This can be evaluated by using the internal five-fold cross-
validation and external independent validation scheme as
described in the Materials and Methods section. In the following
section, we firstly assess the performance of these obtained models
based on these two methods, and then carry out the systematical
drug-target interaction predictions to further verify the usefulness
of the models in comprehensive prediction.
Figure 1. The flowchart of the modeling procedure.
doi:10.1371/journal.pone.0037608.g001
.
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To construct the four classification models using the Random
Forest method, we firstly validated the predictive performance of
these models by the internal five-fold cross-validations. Table 1
shows that these RF models for the internal validation perform
consistently well in predicting the binding (average SE 78.50%)
and the non-binding (average SP 85.37%) patterns, with an
average concordance of 82.26% and an average AUC of 89.65,
indicating the strong robustness and capability of the models for
prediction of the interactions between drugs and targets.
Additionally, the obtained ROC curve (Figure 2) suggests that
the RF method can catch sufficient information to detect the drug-
target interactions at high true-positive rates against low false-
positive rates at any threshold. For example, in the RF Model I,
when the true positive rate reaches 40% the false positive rate is as
low as ,2%, and when the true positive rate is 60% the false
positive rate is still low as ,4%.
Subsequently, we used four external independent validations to
further assess the generalization ability of these models, i.e., the
‘‘general’’ prediction, the ‘‘new-drug vs known-target’’ prediction,
‘‘new-target vs known-drug’’ prediction and ‘‘new-drug vs new-
target’’ prediction (Table 1). For the test set I, the RF Model I
acquires a sensitivity of 80.99%, a specificity of 84.66% and a
concordance of 82.83%, which are comparable to the results
obtained for the internal validation. This suggests that the risk of
over-fitting problem is quite low for the obtained models. For the
test set II and test set III, RF Model II and III obtain a sensitivity
of 73.66% and 52.20%, a specificity of 83.52% and 92.15% and a
concordance of 79.09% and 74.53%, respectively. Evidently, the
Model II exhibits much better results than model III, and such
Figure 2. The ROC curves of the RF and SVM in internal five-fold cross validation for (a) Model I, (b) Model II, (c) Model III and (d)
Model IV.
doi:10.1371/journal.pone.0037608.g002
Table 1. Statistics of the prediction performances.
Model SE (RF/SVM) SP (RF/SVM) CO (RF/SVM) AUC (RF/SVM)
Training Test Training Test Training Test Training Test
Model I 79.58%/76.31% 80.99%/77.50% 84.11%/85.85% 84.66%/85.91% 81.84%/81.08% 82.83%/81.71% 89.50/88.97 90.55/89.91
Model II 81.18%/77.66% 73.66%/74.11% 83.89%/86.11% 83.52%/85.49% 82.50%/81.78% 79.09%/80.38% 90.31/89.79 86.50/87.19
Model III 81.33%/77.56% 52.20%/55.17% 83.22%/85.35% 92.15%/93.62% 82.25%/81.34% 74.53%/76.66% 89.81/89.04 82.77/84.90
Model IV 71.90%/66.41% 32.52%/36.48% 90.25%/88.07% 91.21%/92.42% 82.46%/78.88% 66.09%/68.48% 88.99/85.62 72.64/75.47
Average 78.50%/74.49% 59.84%/60.82% 85.37%/86.35% 87.89%/89.36% 82.26%/80.77% 75.64%/76.81% 89.65/88.36 83.13/83.93
The AUC (ROC score) is the area under the ROC curve, normalized to 100 for a perfect inference and 50 for a random inference.
doi:10.1371/journal.pone.0037608.t001
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with the sensitivity of 74.11% and 55.17% for set II and set III,
respectively. The reason might be due to: (1) the test set II blends
better with the training set II than the test set III with the training
set III; (2) the choice of receptor descriptors in this study have
more relevant than that of ligand descriptors; and (3) the smaller
information space of the receptor protein compared with the
ligand chemical in the training set leads to the lack of the available
targets information for the test dataset. The predictability for test
set IV is relatively weak, with a sensitivity of 32.52%, a specificity
of 91.21% and a concordance of 66.09%, respectively. Compared
with the previous study, the model built based on this set is not
only not improved but also is quite poor in the performance, which
may be closely related to the universality and the sample size of
test set IV that is not sufficient enough to represent the general
cases. The ROC curves of the four external validations are shown
in Figure 3, revealing that the prediction capability of the models
built on different sets follows an order of Set I.Set II.Set III.Set
IV, with a range of the AUC values from 72.64 to 90.55. The
above results suggest that the RF learning methods can perform
better when a lot of drugs and targets interaction information is
available in the learning dataset. Additionally, it also suggests that
the adopted encoding method is biologically relevant and enable
to efficiently capture the information involved in receptor-ligand
interactions.
Based on the same training and test sets as RF, SVM is also
applied to build the models. For all the internal validation sets and
external set I, the SVM model is slightly worse in both the
concordance and the sensitivity than the RF ones. For the external
sets II, III and IV, the SVM model is slightly better in the
sensitivity, specificity and concordance. The consistency in model
performance of the two methods further indicates that these
models are robust and reliable for predicting the multiple drug-
target interactions. Based on this, we conclude that the conserved
binding patterns that are common to the protein families such as
GPCRs, nuclear receptors, ion channels and enzymes, can be
effectively detected by our proposed approach. It is worth noting
that all these models can definitely identify the negative samples
(non-interaction) with a quite high specificity from 83.22% to
93.62% for all datasets although the negative samples are initially
randomly produced. This from a statistical point of view
demonstrates that the drug-receptor recognition is quite specific,
thus to find a new drug by chance should be extremely difficult.
In principle, the applicability domain of a classification model is
calculated on the basis of the range of individual samples in the
training set that the minimum and maximum values of each
feature were obtained by considering all the samples of the set. In
this work, in order to reduce the dimensionality of the descriptor
pool, to eliminate the correlations among variables as well as to
retain the information restored in the dataset as much as possible,
the principle component analysis (PCA) [40] is applied to the
current datasets for analyzing the applicability domain of the
obtained models. The distribution of all samples of Model I using
the first three PCs is shown in Figure 4 (see others in Supporting
Information S7, S8, S9). It can be seen that training and test sets
were well distributed in ‘‘chemical-biological’’ space. These results
suggest that the applicability domain of these models covers a large
part of the whole ‘‘chemical-biological’’ space.
After confirming the usefulness of our method using the internal
five-fold cross-validations and the four external independent
validations, we have also conducted a blind testing using an
independent dataset obtained from the KEGG database (http://
www.genome.jp/kegg/) apart from DrugBank database. In total,
491 compounds and 979 proteins (including enzymes (n=654),
Figure 3. The ROC curves of the RF and SVM in four independent external validations for (a) Model I, (b) Model II, (c) Model III and
(d) Model IV.
doi:10.1371/journal.pone.0037608.g003
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(n=26)) were extracted from this database (Supporting Informa-
tion S10). The RF Model I for the four datasets obtains an average
sensitivity of 47.51%, an average specificity of 74.93% and an
average concordance of 61.64% (Table 2). The predicted results
for the GPCR and nuclear receptor datasets are fairly good with
the sensitivity up to 80.31% and 91.57%, respectively. However,
we also observed that the RF Model I might not be capable of
predicting the enzyme and ion channel datasets, the obtained
sensitivity values are less than 55%. The projection of the first
three principal components (Figure 5) shows that most samples of
these two datasets deviate from the training dataset of the
developed RF model I, which can effectively explain the obtained
results. Additionally, the ROC curves in Figure 6 indicate that our
methods perform much better than a random inference for the
four target protein families, with a range of the AUC value from
66.58 to 82.29. As compared with the recent bipartite graph
learning (BGL) model [38] (Table 2), the sensitivity of our
proposed approach are much better except the enzyme dataset. It
should be also pointed out that our method has the lower
specificity and concordance, which might indicate that the
negative samples randomly produced from the blind testing
dataset contain the potential interaction relationships. All these
further suggest that the learning algorithms based on the general
chemicals and proteins properties that are related to drug-target
interactions, and therefore allow our approach to successfully
make predictions. However, we have to confess that there are still
a large space to improve the model performances with the
development of new descriptors for chemicals and proteins, and
even mathematical methods.
In addition, using the training set of the Model I, we analyzed
the computational cost of the RF and SVM methods for the
internal five-fold cross-validation process, which was implemented
on a Dell computer (Redhat Linux Operating System) with
2.8 GHz AMD Phenom (tm) II X6 1055T processer and 12 GB
RAM. Due to the complexity of the ‘‘learning’’ phase scales with
the square of the ‘‘number of training compounds times the
number of training proteins’’, the computation time of SVM
(10.86 hours) is much slower than that of the RF (4.53 hours)
approach [20]. This indicates that our proposed RF approach
works better in terms of computational efficiency.
Comprehensive Prediction for Potential Drug-Target
Interactions
The prediction of drug-target interactions can be directly
applied to completing the genome annotations, investigating the
drug specificity and promiscuity, and finding the targets for
diseases. However, the overall pattern of the interaction interface
between the chemical space and biological systems is too large and
complex to be captured. For simplicity, the enzyme which has
been extensively studied as a class of important drug target family
was selected here to illustrate our models’ applications of
predicting the potential drug-target interactions. A total of 175
enzymes in the DrugBank database were matched with each of
6511 drugs to conduct the comprehensive drug-target interaction
prediction using the general RF Model I.
The results show that, in general, two compounds sharing high
structural similarity tend to interact with similar target proteins.
Likewise, two proteins with high sequence similarity tend to
interact with similar drugs. For instance, two structurally similar
drugs Adenosine-59-Diphosphate (DB03431) and Guanosine-59-
Diphosphate (DB4315) were predicted to act on 166 common
targets. This indicates a strong interrelation between the receptor
partners with their binding counterpart. In addition, we also find
that the places for the top scoring drug-target interactions are
mainly occupied by several categories of enzymes and drugs,
where the enzymes are usually highly homologous such as
Prostaglandin G/H synthase 1 and Prostaglandin G/H synthase
2 and the drugs share certain common substructures such as
Figure 4. The distribution of all samples of model I using the first three principal components.
doi:10.1371/journal.pone.0037608.g004
Table 2. The predicted results for the blind testing sets by
the RF model 1.
Dataset SE (RF/BGL) SP(RF/BGL) CO(RF/BGL) AUC(RF/BGL)
Enzyme 35.82%/57.40% 82.70%/99.50% 59.26%/–– 67.43/90.40
GPCR 80.31%/23.40% 55.64%/99.90% 67.98%/–– 72.95/89.90
Ion channel 54.09%/27.10% 73.38%/99.60% 63.73%/–– 66.58/85.10
Nuclear receptor 91.57%/14.80% 39.76%/99.90% 65.66%/–– 82.29/84.30
Average 47.51%/–– 74.93%/–– 61.64%/–– 66.68/––
doi:10.1371/journal.pone.0037608.t002
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nine Dinucleotide (DB03147). Interestingly, this demonstrates that
only a few families of enzymes and drugs account for the top
scoring interactions, which is completely supported by a previous
model established based on the bipartite graph learning algorithm
[38]. Meanwhile, the results also demonstrate that our RF
approach offers better predictions for proteins/chemicals that
have been extensively studied and for which many ligands/
receptors are known. These results further imply that our
proposed methods are able to learn, i.e., the more information is
provided, the better the prediction.
Here, we take the top 10 scoring novel interactions as examples
to illustrate the above findings. As shown in Table 3, compound
Bromfenac (DB00963) is predicted to act on Prostaglandin G/H
synthase 1 with a score of 0.992. Actually, this interaction has been
confirmed and was annotated in DrugBank database [41]. For
Asparagine synthetase [glutamine-hydrolyzing], a new ligand
Indomethacin (DB00328) is predicted to bind to it with the score
of 0.984, which might be hinted by an indirect experiment in
which the Asparagine synthetase expression level was indeed
upregulated by this compound [42]. Additionally, Oxyphenbuta-
zone (DB03585), as a well-known nonsteroidal anti-inflammatory
agent, binds to the cyclooxygenase (COX) Prostaglandin G/H
synthase 1 and Prostaglandin G/H synthase 2 with the same
binding scores of 0.982. This is supported by the fact that the
nonsteroidal anti-inflammatory drugs could produce therapeutic
activities through the inhibition of cyclooxygenase [43]. With no
exception, for all the remaining interactions, the predicted ligands
of certain receptors are invariably similar in structure with those
confirmed ligands as mentioned above. All these outcomes
enhance the strength of our proposed methods for realistic drug-
target interaction prediction application.
Subsequently, a comprehensive network describing the drug-
target interactions was constructed. In order to make it clear and
simple, the top 500 scoring drug-target interactions were used to
generate a bipartite graph of drug-target interactions for
illustrating the complex relationships between drugs and enzymes,
in which a compound and a protein are connected to each other if
the protein is a predicted target of the compound. Figure 7 shows a
global view of this network with color and shape-coded nodes. To
explore the topological and global properties of this drug-target
network, the centralization, heterogeneity and node degree
distribution were analyzed [44]. The centralization and heteroge-
neity analysis shows the network centralization and heterogeneity
degrees are 0.463 and 3.661, respectively, indicating that a few
Figure 5. The distribution of the training dataset for Model I
and blind testing dataset (including enzymes, GPCRs, ion
channel and nuclear receptors) using the first three principal
components.
doi:10.1371/journal.pone.0037608.g005
Figure 6. The ROC curves of blind independent validation
results for four target protein families.
doi:10.1371/journal.pone.0037608.g006
Table 3. The predicted top 10 scoring novel drug-target interactions.
Protein name (UniProt ID) Drug generic name (DrugBank ID) Binding score
NAD(P)H dehydrogenase [quinone] 1 (P15559) Flavin-N7 protonated-adenine dinucleotide (DB02332) 0.996
NAD(P)H dehydrogenase [quinone] 1 (P15559) NADH (DB00157) 0.994
Alcohol dehydrogenase [NADP+] (P14550) NADH (DB00157) 0.992
Prostaglandin G/H synthase 1 (P23219) Bromfenac (DB00963) 0.992
Prostaglandin G/H synthase 1 (P23219) D-allopyranose (DB03989) 0.990
Cholinesterase (P06276) Beta-D-Glucose (DB02379) 0.988
Cholinesterase (P06276) D-Allopyranose (DB03989) 0.986
Asparagine synthetase [glutamine-hydrolyzing] (P08243) Indomethacin (DB00328) 0.984
Prostaglandin G/H synthase 1 (P23219) Oxyphenbutazone (DB03585) 0.982
Prostaglandin G/H synthase 2 (P35354) Oxyphenbutazone (DB03585) 0.982
doi:10.1371/journal.pone.0037608.t003
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target space is biased toward certain compounds and proteins.
Consistent with this, the node degree distribution analysis demon-
strates that most nodes have low degrees with only a small proportion
of components (hub) interacting with the multiple partners (Figure 8)
in this network, and this further suggests that the network is not
generated at random. Therefore, we concluded that this predicted
drug-target interaction network tends to be controlled by only a small
number of drugs and targets, which have a lot of available
pharmacological interaction information in the learning dataset.
Novel Target Prediction for Existing Drugs
Finding new therapeutic indications for the existing drugs
represents an efficient parallel approach to the drug discovery,
since existing drugs already have extensive clinical history and
toxicological information [45]. All above models and the derived
information show that new potential drug-target interaction can be
effectively predicted by our proposed approach. And to achieve
this goal, i.e., to further predict the novel targets for the existing
drugs by using our models, two representative small molecules
MDMA (DB01454) and Resveratrol (DB02709) were selected
presently to illustrate the models’ applications, since the compre-
hensive drug-target interaction network is immensely huge.
MDMA is a known psychoactive drug, which is also effective in
the treatment of post-traumatic stress disorder [46]. And
Resveratrol has the potential of creating anti-inflammatory and
anticancer effects [47,48]. The selection of these two molecules is
owing to that their related target information has been reported in
Figure 7. Predicted drug-enzyme interactions with the 500 highest scores, where the triangle and circle nodes indicate the enzymes
and drugs, respectively; the orange and purple triangle indicate the known targets and new predicted targets, respectively; the
green and red circle indicate the known drugs and new predicted drugs, respectively; the gray and red edges indicate the known
interactions and newly predicted interactions, respectively.
doi:10.1371/journal.pone.0037608.g007
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RF Model I and RF Model II. The potential targets of these two
molecules are predicted from the pool of all 3987 target proteins
using the RF Model I and RF Model II, respectively (with the
whole prediction results provided in Supporting Information S11
and S12).
The obtained results show that MDMA targets 367 different
proteins including seven proteins with the binding scores .0.65,
i.e., 5-hydroxytryptamine 2A receptor, 5-hydroxytryptamine 2B
receptor, 5-hydroxytryptamine 2C receptor, Synaptic vesicular
amine transporter, Sodium-dependent serotonin transporter,
Sodium- dependent dopamine transporter and Sodium-dependent
noradrenaline transporter, all of which receptors have been in fact
well demonstrated as the MDMA targets [49–53]. Table 4 lists the
top 20 scoring targets with the binding scores .0.75. Interestingly,
it is found that MDMA binds to the A-1A adrenergic receptor
(ADRA1A, binding score=0.764) and A-2A adrenergic receptor
(ADRA2A, binding score=0.802), which are the targets of 4-
methoxyamphetamine (DB01472) [22], a compound structurally
similar to MDMA (Figure 9). In addition, this is also consistent
Figure 8. The node degree distribution of the top 500 scoring drug-enzyme interactions.
doi:10.1371/journal.pone.0037608.g008
Table 4. Predicted top 20 scoring target proteins of MDMA.
Protein name UniProt ID Binding score
Beta-1 adrenergic receptor P08588 0.820
Carbonic anhydrase 2 P00918 0.810
Prothrombin P00734 0.804
Alpha-2A adrenergic receptor P08913 0.802
Prostaglandin G/H synthase 2 P35354 0.800
Dipeptidyl peptidase 4 P27284 0.798
Acetylcholinesterase P22303 0.796
Nitric-oxide synthase, endothelial P29474 0.794
Beta-2 adrenergic receptor P07550 0.794
Prostaglandin G/H synthase 1 P23219 0.784
Gag-Pol polyprotein P12497 0.778
Nitric oxide synthase, inducible P35228 0.770
Glutamate receptor 2 P42262 0.770
Alpha-2C adrenergic receptor P18825 0.768
5-hydroxytryptamine 2A receptor P28223 0.766
Alpha-1A adrenergic receptor P35348 0.764
cAMP-dependent protein kinase catalytic subunit alpha P17612 0.760
Gag-Pol polyprotein P03366 0.758
Gamma-aminobutyric-acid receptor subunit alpha-1 P14867 0.754
Gag-Pol polyprotein P03367 0.752
doi:10.1371/journal.pone.0037608.t004
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caused by the activation of ADRA1A, together with the Beta-3
adrenergic receptor [54,55]. And the Beta-3 adrenergic receptor is
also correctly predicted to interact with the MDMA (binding score
0.676). All these suggest the biological relevance of this drug-target
interaction prediction.
Resveratrol is predicted to interact with 318 different proteins,
among which four have the binding score .0.57, i.e., Prostaglan-
din G/H synthase 1, Prostaglandin G/H synthase 2, Ribosyldihy-
dronicotinamide dehydrogenase [quinone] and Casein kinase II
subunit a, and all these proteins have been well demonstrated
interacting with this compound [56,57]. Besides, the proteins of
Estrogen receptor, Estrogen receptor beta and Xanthine dehy-
drogenase/oxidase, which are new to RF Model II, are also
predicted to interact with this compound (binding score .0.55).
Actually, these predicted interactions have been identified and
were annotated in Herbal Ingredients’ Targets Database (HITD)
(http://lifecenter.sgst.cn/hit/welcome.html), although they have
not been collected in the DrugBank database. Interestingly
Estrogen receptor and Estrogen receptor beta are also the well-
known targets of Diethylstilbestrol (DB00255), a chemical sharing
high structure similarity with Resveratrol, which suggests that our
prediction methods using the protein-ligand space allows sharing
information between unrelated (low sequence similarity) proteins
via the similarities shared by their ligands. Additionally, the
sequence similarities of Estrogen receptor and Xanthine dehydro-
genase/oxidase are only ,7%; further indicating our approach
could identify unrelated target proteins of chemical compounds
that the standard similarity-based methods fail to detect. All these
outcomes demonstrate that the proposed models could be effective
tools to directly explore novel targets for those ‘‘old’’ drugs.
Novel Drug Prediction for Existing Targets
Most drugs are designed to target a particular protein of certain
disease. However, a key feature in the drug-target interaction is
that drugs often bind to multiple targets, known as polypharma-
cology or drug promiscuity. Therefore, the new potential functions
of the ‘‘old’’ targets for seeking novel treatment channel of relevant
diseases might be acquired through the discovery of novel drugs
for those existing targets. In this work, our models have exhibited a
powerful ability to predict novel drugs for the ‘‘old’’ targets.
Presently, a typical protein of Thymidine kinase from herpes
simplex virus (UniProt ID Q9QNF7) [58], which is new to the RF
Model III, is taken as an example to clarify the application of our
model, since the drug-target network is too huge to be provided
completely. The selection of this protein is due to that its related
drug information has been reported in literature, but has not been
adopted in training of the RF Model III. Using the model, the
potential drugs of this protein are predicted from the pool of all
6511 drugs (with all results depicted in Supporting Information
S13).
The obtained outcomes demonstrate that this Thymidine kinase
is predicted to interact with 1484 different small molecules. By
investigating the chemical structure of these compounds, we find
that these predicted ligands are structurally diverse but exhibit a
non-random and clustering tendency in the structural and
physicochemical properties. To further quantitatively describe
these properties, a clustering analysis based on the hierarchical
cluster algorithm [59,60] was conducted (The whole clustering
analysis information are provided in Supporting Informaton S14,
S15, S16). The obtained results show that the compounds are
distinctly separated into four clusters, i.e., Cluster A (318
molecules), Cluster B (1129 molecules), Cluster C (24 molecules)
and Cluster D (13 molecules) (the detailed clustering analysis
results are provided in Supporting Information S17).
Table 5 shows that the top 10 highest scoring predictions chosen
from different ligand families. For cluster A, the structurally similar
chemicals NADH (DB00157), Adenosine-59-Diphosphate
(DB03431), Guanosine-59-Diphosphate (DB03431) and Nicotin-
amide-Adenine-Dinucleotide (DB01907) are predicted to bind to
this enzyme with the binding score .0.80. Actually, Adenosine-59-
Diphosphate is the well-known ligand of a homologous Thymidine
kinase (UniProt ID P03176) [22]. With regard to cluster B,
compound Idoxuridine (DB00249) is predicted to bind to this
enzyme with a binding score 0.762, such interaction has been well-
known confirmed and was annotated in DrugBank database [61].
As for cluster C, we do not found any annotated information but it
does not mean that they (Hesoheme and Heme) are not potential
ligands for this enzyme. In terms of cluster D, this enzyme is found
to interact with Pentostatin (DB00552) (binding score 0.656), a
chemical sharing a common substructure with Penciclovir
(DB00299), which is the known ligand of another homologous
Thymidine kinase (UniProt ID P06478) [23]. All these imply that
our prediction approaches using the protein-ligand space allows
sharing information between scaffold hopping chemicals via the
similarities shared by their receptors. Additionally, the other three
well-known ligands of this enzyme, i.e., Vidarabine (DB00194),
Valaciclovir (DB00577) and Trifluridine (DB00432) [62–64], were
also screened out with a binding score .0.65. However, as shown
in Figure 10, Trifluridine and Idoxuridine are not structurally
similar with Vidarabine and Valaciclovir, indicating that our
model is useful to identify novel scaffold ligands of the receptors.
Besides, it also suggests that the underlying patterns in the multiple
drug-target interactions can be captured by this proposed
approach. Therefore, we concluded that our approach is capable
of detecting novel candidates for those ‘‘old’’ targets.
Discussion
Traditional drug discovery is largely based upon ‘one molecule-
one target-one disease’ model, but there is a growing recognition
that drugs work by targeting multiple proteins [65,66]. The
biological network and pathways possessing inherent redundancy
and robustness imply that regulating a single target might fall short
of producing the desired therapeutic effects [67,68]. Therefore, the
development of multiple drug-target interaction prediction models
to investigate disease-associated drug-target network will undoubt-
edly be an enduring trend for future drug discovery.
In this report, by integrating the information from the chemical
structure, protein sequence and pharmacological drug-target
interaction data, we developed a set of in silico models using a
large-scale dataset to predict the potential drug-target interactions.
All models were evaluated and verified by both internal and
external validations. The outcomes demonstrated the strength of
our proposed method for predicting drug-target interaction, which
indicates that the conserved binding patterns between drugs and
targets can be extracted by our approach from the dataset that
contains adequate feature vectors for chemical-protein pairs.
Selecting a suitable encoding of the compounds and proteins
information is one of the main computational challenges for the
prediction of drug-target interactions using in silico tools. In our
case, we apply DRAGON molecular descriptors and structural
and physicochemical properties descriptors to represent ligands
and targets, respectively. Our successful predictions indicate that
this adopted chemical and proteins encoding can effectively
distinguish the drug-target binding pairs from the non-binding
pairs. Additionally, the choice of merging protein and ligand
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encode the protein-ligand pair in the joint space) was also adopted
in this study, which means that the structural similarity between
the two different drugs/targets are independently evaluated by the
same measure and are then multiplied to give the overall
similarity. Although this description prevents from separate tuning
of similarity measures in the protein and ligand spaces when using
the SVM kernel approach, it is simple and effective to evaluate the
similarity of drug-target pairs [69].
In this study, we proposed the RF approach to predict drug-
target interactions, which is a new contribution in the field of drug
discovery and development. As well known, RF introduces two
sources of randomness into the trees: random training set
(bootstrap) and random input vectors. Each tree is grown using
a bootstrap sample of training data at each node, with best split
chosen from random sample of mtry variables instead of all
variables. The Bagging (bootstrap aggregating) method causes the
low bias and high variance of the unpruned trees, but the variance
is reduced by averaging the bootstrapped trees. Because each node
is split using the best among a subset of predictors randomly
chosen at that node, this strategy turns out to perform very well
compared with many other classifiers such as ANN and SVM, and
is more robustness against overfitting. However, it should be also
pointed out that SVM allows us to use a tensor product space, with
no extra calculation time with respect to the joint space, and
versatile choice of similarity measures for proteins and ligands,
which is a clear advantage of SVM with respect to this proposed
RF approach.
As shown in the Results section, the proposed method enables to
identify the unrelated proteins that may share structurally similar
pockets in the 3D space, the advantage effect of which is derived
from the learning ligand similarities. If the unrelated receptors do
not possess similar ligands in the learning dataset, then the protein
encoding (structural and physicochemical properties derived from
their primary sequence) plays a key role for the unrelated targets
identification, which have been well applied for the prediction of
protein structural and functional classes, protein-protein interac-
tions and subcellular locations [70–72]. Particularly, most
descriptors of this encoding such as Composition of Solvent
Accessibility and Distribution of Charge are highly useful for
representing and distinguishing interaction profiles, which is
essential for the successful application of statistical learning
methods in predicting the interaction profiles between drugs and
targets [73]. Although this encoding can effectively describe the
interaction profiles of the whole protein, it is limited by the
description and extraction of the 3D structure features of the
ligand-binding domains. Therefore, obtaining optimal protein
encoding method will require further research.
The main advantages of our proposed approach are summa-
rized as follows: 1) In building models, no explicit procedure is
needed to select the information shared among all drug-target
recognitions. 2) Our system is suitable for simultaneously screening
huge numbers of drug candidates and candidate targets from a
systematic level; 3) Compared with the structure-based simulation
methods, this approach is not limited by the 3D structure data of
targets; 4) The structure similarity of a chemical with ligands that
bind to proteins which this compound is not known to bind can be
used by our method to discover unknown activities. 5) The system
is able to identify those ligands/receptors that exhibit scaffold
hopping/low sequence similarity; and 6) this approach can aid in
discovery of multi-target drugs by recognizing the group of
proteins targeted by a particular ligand. Based on all these, we
Table 5. Predicted top 10 scoring drugs of Thymidine kinase.
Drug generic name
DrugBank
ID
Binding
score Cluster
NADH DB00157 0.870 A
Nicotinamide-Adenine-Dinucleotide DB01907 0.848 A
Adenosine-59-Diphosphate DB03431 0.844 A
Guanosine-59-Diphosphate DB04315 0.808 A
Acetate Ion DB04184 0.792 B
Mesoheme DB02577 0.786 C
Heme DB03014 0.786 C
Idoxuridine DB00249 0.762 B
Pentostatin DB00552 0.656 D
1-Beta-Ribofuranosyl-1,3-Diazepinone DB03185 0.622 D
doi:10.1371/journal.pone.0037608.t005
Figure 9. The chemical structures of 4-methoxyamphetamine
(DB01472) and MDMA (DB01454).
doi:10.1371/journal.pone.0037608.g009
Figure 10. The chemical structure of compounds for (a)
Idoxuridine (DB00249), (b) Trifluridine (DB00432), (c) Valaci-
clovir (DB00577) and (d) Vidarabine (DB00194).
doi:10.1371/journal.pone.0037608.g010
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mindset’’ is appropriate for modeling and understanding complex
drug-target interaction networks. This perspective could devote to
the recapturing of known small molecules and the explication of
mechanisms of drug side effects, and finally is anticipated to help
fill in the existing gap between chemical genomics and network
pharmacology.
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